NCT07026370

Brief Summary

The Chinese Population Health and Multimorbidity Study (CPHMS; initially named China Pulmonary Health Study, CPHS) was a large-scale epidemiological survey designed to investigate the pulmonary health of Chinese adults aged 20 years or older leveraging a multistage stratified sampling scheme between 2011 and 2014 in mainland China. Briefly, a total number of 57,779 local residents were recruited from 10 representative provinces and municipalities and were invited to participate in the study. A final number of 50,991 adults who met the major inclusion criteria could be considered in further analyses. In order to investigate the changes of pulmonary health and disease status (e.g. occurrence and development of chronic respiratory diseases and other important relevant multimorbidities, lung function indices, etc.) and corresponding impact factors in the CPHMS study population, we plan to initiate the first round of follow-up investigation between 2025 and 2027 (planned) , i.e. more than 10 years after the baseline survey.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50,991

participants targeted

Target at P75+ for all trials

Timeline
14mo left

Started Jan 2011

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress93%
Jan 2011Jun 2027

Study Start

First participant enrolled

January 1, 2011

Completed
14.4 years until next milestone

First Submitted

Initial submission to the registry

May 30, 2025

Completed
19 days until next milestone

First Posted

Study publicly available on registry

June 18, 2025

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2027

Last Updated

March 5, 2026

Status Verified

March 1, 2026

Enrollment Period

16.5 years

First QC Date

May 30, 2025

Last Update Submit

March 4, 2026

Conditions

Chronic Respiratory DiseasesMalignant TumorsCardiovascular and Cerebrovascular DiseasesEndocrine and Metabolic DiseasesMultimorbidities

Keywords

MultimorbiditiesEpidemiological surveyCohortPopulation medicine

Outcome Measures

Primary Outcomes (1)

  • Occurrence of multimorbidities

    Occurrence of chronic respiratory diseases, cardiovascular and cerebrovascular diseases, malignant tumors, and/or metabolic diseases, etc.

    Since the year of baseline survey till the year of 2025 and 2027 (the first round of follow-up investigation of CPHMS)

Secondary Outcomes (4)

  • Changes of lung function, forced expiratory volume in one second (FEV1)

    Since the year of baseline survey till the year of 2025 and 2027 (the first round of follow-up investigation of CPHMS)

  • Changes of lung function, forced vital capacity (FVC)

    Since the year of baseline survey till the year of 2025 and 2027 (the first round of follow-up investigation of CPHMS)

  • Changes of lung function, FEV1/FVC

    Since the year of baseline survey till the year of 2025 and 2027 (the first round of follow-up investigation of CPHMS)

  • Changes of lung function, the percentage of measured FEV1 value to the predicted value (FEV1%pred)

    Since the year of baseline survey till the year of 2025 and 2027 (the first round of follow-up investigation of CPHMS)

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

A total number of 50,991 adults aged 20 years or older from 10 representative provinces and municipalities of China participated in the CPHMS baseline survey between 2011 and 2014. In the follow-up investigation, ideally all the baseline participants should be contacted.

You may qualify if:

  • (1) the individuals who participated in the CPHMS baseline survey;
  • (2) their ID number and phone number are available;
  • (3) sign the informed consent.

You may not qualify if:

  • (1) incapable of taking pre- and post-bronchodilator spirometry tests;
  • (2) request to withdraw the informed consent;
  • (3) terminate due to medical or ethical considerations judged by the investigators and/or ethics committee.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

China-Japan Friendship Hospital

Beijing, Beijing Municipality, 100029, China

Location

Related Publications (3)

  • Wang C, Xu J, Yang L, Xu Y, Zhang X, Bai C, Kang J, Ran P, Shen H, Wen F, Huang K, Yao W, Sun T, Shan G, Yang T, Lin Y, Wu S, Zhu J, Wang R, Shi Z, Zhao J, Ye X, Song Y, Wang Q, Zhou Y, Ding L, Yang T, Chen Y, Guo Y, Xiao F, Lu Y, Peng X, Zhang B, Xiao D, Chen CS, Wang Z, Zhang H, Bu X, Zhang X, An L, Zhang S, Cao Z, Zhan Q, Yang Y, Cao B, Dai H, Liang L, He J; China Pulmonary Health Study Group. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018 Apr 28;391(10131):1706-1717. doi: 10.1016/S0140-6736(18)30841-9. Epub 2018 Apr 9.

    PMID: 29650248RESULT

  • Huang K, Yang T, Xu J, Yang L, Zhao J, Zhang X, Bai C, Kang J, Ran P, Shen H, Wen F, Chen Y, Sun T, Shan G, Lin Y, Xu G, Wu S, Wang C, Wang R, Shi Z, Xu Y, Ye X, Song Y, Wang Q, Zhou Y, Li W, Ding L, Wan C, Yao W, Guo Y, Xiao F, Lu Y, Peng X, Zhang B, Xiao D, Wang Z, Chen Z, Bu X, Zhang H, Zhang X, An L, Zhang S, Zhu J, Cao Z, Zhan Q, Yang Y, Liang L, Tong X, Dai H, Cao B, Wu T, Chung KF, He J, Wang C; China Pulmonary Health (CPH) Study Group. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study. Lancet. 2019 Aug 3;394(10196):407-418. doi: 10.1016/S0140-6736(19)31147-X. Epub 2019 Jun 20.

    PMID: 31230828RESULT

  • Xiao D, Chen Z, Wu S, Huang K, Xu J, Yang L, Xu Y, Zhang X, Bai C, Kang J, Ran P, Shen H, Wen F, Yao W, Sun T, Shan G, Yang T, Lin Y, Zhu J, Wang R, Shi Z, Zhao J, Ye X, Song Y, Wang Q, Hou G, Zhou Y, Li W, Ding L, Wang H, Chen Y, Guo Y, Xiao F, Lu Y, Peng X, Zhang B, Wang Z, Zhang H, Bu X, Zhang X, An L, Zhang S, Cao Z, Zhan Q, Yang Y, Liang L, Liu Z, Zhang X, Cheng A, Cao B, Dai H, Chung KF, He J, Wang C; China Pulmonary Health Study Group. Prevalence and risk factors of small airway dysfunction, and association with smoking, in China: findings from a national cross-sectional study. Lancet Respir Med. 2020 Nov;8(11):1081-1093. doi: 10.1016/S2213-2600(20)30155-7. Epub 2020 Jun 26.

    PMID: 32598906RESULT

MeSH Terms

Conditions

Cerebrovascular DisordersNeoplasmsMetabolic Diseases

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesNutritional and Metabolic Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Ph.D.

Study Record Dates

First Submitted

May 30, 2025

First Posted

June 18, 2025

Study Start

January 1, 2011

Primary Completion (Estimated)

June 30, 2027

Study Completion (Estimated)

June 30, 2027

Last Updated

March 5, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Locations

CN(1)